

08/016, 37

(FILE 'HOME' ENTERED AT 14:06:34 ON 11 AUG 1997)

FILE 'CPLUS' ENTERED AT 14:06:38 ON 11 AUG 1997

L1           1 S NITRIC OXIDE(3W) (FERRIHEMOGLOBIN?)/TI  
L2           255 S (SICKLE CELL ANEMIA)/TI  
L3           44551 S (NO OR NITRIC OXIDE?)/TI  
L4           0 S L2 AND L3  
L5           0 S L2 AND (NITROSYLAT?) (2A) (HEMOGLOBIN? OR HB)  
L6           17045 S (HEMOGLOBIN?)/TI  
L7           47 S L2 AND L6  
L8           250 S (S-NITROS?)/TI  
L9           0 S L7 AND L8  
L10          0 S L2 AND L8  
L11          23 S (NITROSYLAT?) (2A) (HEMOGLOBIN? OR HB)  
L12          2 S L11 AND (SICKLE CELL?)  
L13          26225 S (BLOOD SUBSTITUTE?)  
L14          1644 S (SICKLE CELL ANEMIA?)  
L15          6 S L13 AND L14  
L16          2 S (ISOTHIOCYANATE) AND (BLOOD SUBSTITUTE?)  
L17          1 S (NITRIC OXIDE? DONOR?) AND (BLOOD SUBSTITUTE?)  
L18          23 S (NITROSYLAT?) (2A) (HEMOGLOBIN? OR HB)  
L19          2 S L18 AND (SICKLE CELL ANEMIA?)  
L20          26225 S (BLOOD SUBSTITUTE?)  
L21          3 S L18 AND L20  
L22          0 S (NITROSLAT?) (2A) (BLOOD SUBSTITUTE?)  
L23          1188 S (NO-DONOR?)  
L24          0 S L23 AND (SICKLE CELL ANEMIA?)  
L25          2 S L23 AND (BLOOD) (2A) (SUBSTITUTE?)

L1 ANSWER 1 OF 1 CAPLUS COPYRIGHT 1997 ACS  
1993:503075 Document No. 119:103075 **Nitric oxide**  
binding to human **ferrihemoglobins** crosslinked between  
either .alpha. or .beta. subunits. Alayash, Abdu I.; Fratantoni,  
Joseph C.; Bonaventura, Celia; Bonaventura, Joseph; Cashon, Robert  
E. (Cent. Biol. Eval. Res., Food Drug Adm., Bethesda, MD, 20892,  
USA). Arch. Biochem. Biophys., 303(2), 332-8 (English) 1993.  
CODEN: ABIA4. ISSN: 0003-9861.

AB The interactions between NO and oxidized human Hb were examd.,  
comparing the behavior of unmodified HbA0 with that of two chem.  
modified Hbs. The latter are promising red cell substitute  
candidates due to their lower oxygen affinity and greater stability  
as tetramers. The modified forms examd. were HbA-DBBF, crosslinked  
between the .alpha. chains with bis(3,5-dibromosalicyl) fumarate,  
and HbA-FMDA, modified between the .beta. chains with fumaryl  
monodibromoaspirin. Nitric oxide binding to the oxidized forms of  
these Hbs is biphasic, due to the differing reactivities of .alpha.  
and .beta. chains. The structural modifications result in altered  
rate consts. for NO binding to both .alpha. and .beta. chains. The  
affinity of the ferric hemes for NO is not correlated with their  
oxygen affinities in the ferrous state. In a much slower  
first-order process, the ferric hemes of HbA become reduced. Faster  
and more heterogeneous kinetics are obsd. for redn. of the modified  
Hbs. These results may have physiol. relevance, since endogeneously  
produced NO is now recognized to play an important role in the  
relaxation of vascular smooth muscles. If present in vivo,  
cell-free Hbs exposed to NO become rapidly oxidized. Subsequent  
interactions of NO with ferriHb can result in redox cycling. This  
has the potential of depleting NO and further altering vascular tone  
with rates dependent on structural parameters of the ferriHb that  
are not detd. by oxygen affinity.